Gounder, M. M., Wagner, A. J., Somaiah, N., Riedel, R. F., Schwartz, G. K., Attia, S., … Chawla, S. P. (2016). The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS). In Journal of Clinical Oncology (Vol. 34, pp. TPS11072–TPS11072). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.tps11072

Gounder, Mrinal M., Andrew J. Wagner, Neeta Somaiah, Richard F. Riedel, Gary K. Schwartz, Steven Attia, Albiruni R. A. Razak, et al. “The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS).” In Journal of Clinical Oncology, 34:TPS11072–TPS11072. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps11072.

Gounder MM, Wagner AJ, Somaiah N, Riedel RF, Schwartz GK, Attia S, et al. The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS11072–TPS11072.

Gounder, Mrinal M., et al. “The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. TPS11072–TPS11072. Crossref, doi:10.1200/jco.2016.34.15_suppl.tps11072.

Gounder MM, Wagner AJ, Somaiah N, Riedel RF, Schwartz GK, Attia S, Razak ARA, Cranmer LD, Okuno SH, Milhem MM, Choe-Juliak C, Shacham S, Kauffman MG, Chawla SP. The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS11072–TPS11072.